Methods

For measurement of muscle weights, individual muscles from both sides were dissected, and the average weight was used for each muscle. For RNA isolation, the left gastrocnemius and right femur (which was spun at high speed to remove marrow components) were snap frozen in liquid nitrogen. RNAseq analysis was carried out using the in-house pipeline at The Jackson Laboratory. Trimmomatic (version 0.33) (1) was used to remove adapters and also leading and trailing low quality bases. Reads fewer than 36 bases long were dropped. Reads with more than 50% low-quality bases overall were filtered out, and the remaining high-quality reads were then used for expression estimation. Alignment estimation of expression levels using the EM algorithm for paired-end read data was performed using RSEM (package version 1.2.12) (2); default settings were used for alignment. RSEM uses bowtie2 as aligner to align the mapped reads against the mm10 reference genome. Data quality control was performed using Picard (version 1.95) (http://broadinstitute.github.io/picard/) and bamtools to obtain general alignment statistics from the bam file. Analyses of aligned reads were performed using the edgeR (v3.30.0) (https://www.bioconductor.org/packages/release/bioc/vignettes/edgeR/inst/doc/edgeRUsersGuide.pdf) package in R (v4.0.0) (https://www.R-project.org/). We did not observe any significant differences in either the number of high quality reads or degree of alignment among the different experimental groups. The enrichment of pathways was analyzed using the R package clusterProfiler (3). Pathway analysis was carried out using KEGG (Kyoto Encylopedia of and Genomes) PATHWAY (Available online: http://www.genome.jp/kegg) with a p value cutoff of < 0.05.

For microCT analysis, the left femur, left humerus, and lumbar vertebrae were placed in 70% ethanol or 10% neutral buffered formalin. µCT was performed in a Scanco µCT40 at 8µm3 resolution. Samples were scanned in 70% ethanol 55kVp, 145µA intensity, 300ms. The instrument is calibrated weekly using Scanco phantoms, and all scans passed routine quality control verification. Analysis of femurs, humeri, and vertebrae was conducted using standard protocols, with a lower threshold of 2485 Hounsfield units (HU) for femoral trabeculae, 4932HU for femoral cortex, 2559HU for humeral trabeculae, and 3078HU for vertebral trabeculae (4). Surface renderings were generated corresponding to each of these thresholds.

Proteomic analysis of plasma samples from each group of mice was carried out on the SomaScan Assay as previously described (5, 6). Here, modified aptamer binding reagents (7) were used to assess the levels of ~5,000 in each sample. Because these aptamers were developed based on their ability to detect human proteins, about a third of these do not detect the corresponding mouse proteins. In analyzing the data obtained from the plasma samples, we noted that there were scattered individual values for some proteins that deviated considerably from the mean values in the respective group; for this reason, we carried out the initial analysis of global changes by comparing median values between groups. ELISAs to measure levels of MSTN and murine OPG were performed using kits obtained from R&D Sytems, Inc. Statistical significance was assessed using the unpaired Student’s t- test.

1. Bolger AM, Lohse M, & Usadel B (2014) Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics 30(15):2114-2120. 2. Li B & Dewey CN (2011) RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics 12:323. 3. Yu G, Wang LG, Han Y, & He QY (2012) clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16(5):284-287. 4. Bouxsein ML, et al. (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25(7):1468-1486. 5. Williams SA, et al. (2019) Plasma patterns as comprehensive indicators of health. Nat Med 25(12):1851-1857. 6. Gold L, et al. (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PloS one 5(12):e15004.

www.pnas.org/cgi/doi/10.1073/pnas.2014716117 7. Rohloff JC, et al. (2014) Nucleic Acid Ligands With Protein-like Side Chains: Modified Aptamers and Their Use as Diagnostic and Therapeutic Agents. Mol Ther Nucleic Acids 3:e201.

Figure S1. RNAseq analysis. (A) Bar graph showing the top 50 pathways in exhibiting differentially expressed transcripts between ACRVR2B/Fc-treated and uninjected ground mice. Pathways are -ordered based on p values. Sizes of bars indicate the number of genes within a pathway showing statistically significant differences.

Figure S2. RNAseq analysis. (A) Bar graph showing the top 42 pathways in bone exhibiting differentially expressed transcripts between uninjected flight and uninjected ground mice. Pathways are rank-ordered based on p values. Sizes of bars indicate the number of genes within a pathway showing statistically significant differences.

Figure S3. RNAseq analysis. (A) Bar graph showing the top 50 pathways in skeletal muscle exhibiting differentially expressed transcripts between uninjected flight and uninjected ground mice. Pathways are rank-ordered based on p values. Sizes of bars indicate the number of genes within a pathway showing statistically significant differences.

Table S1. ______

FEMUR (CORTICAL) ground flight ground flight ground flight uninjected uninjected + ACVR2B/Fc + ACVR2B/Fc Mstn -/- Mstn -/- ______

Sub-periosteal area (mm2) 1.778 + 0.020 1.792 + 0.015 1.878 + 0.012 f 1.838 + 0.038 1.855 + 0.018 g 1.770 + 0.019 c Sub-endosteal area (mm2) 0.932 + 0.015 1.003 + 0.014 c 0.915 + 0.009 0.952 + 0.018 m 1.010 + 0.014 g 0.971 + 0.014 Cortical mask (mm2) 0.846 + 0.009 0.788 + 0.008 b 0.963 + 0.012 e 0.886 + 0.022 k,c 0.846 + 0.016 0.799 + 0.015 d Segmented Bone (mm2) 0.843 + 0.009 0.785 + 0.008 b 0.959 + 0.012 e 0.882 + 0.022 k,c 0.842 + 0.016 0.796 + 0.015 d Periosteal perimeter (mm) 4.871 + 0.026 4.891 + 0.023 5.026 + 0.020 f 4.986 + 0.070 4.981 + 0.022 g 4.840 + 0.023 b Endosteal perimeter (mm) 3.611 + 0.029 3.737 + 0.030 c 3.611 + 0.024 3.688 + 0.006 3.752 + 0.020 g 3.666 + 0.021 c Cortical porosity (%) 0.383 + 0.011 0.427 + 0.000 c 0.421 + 0.019 0.446 + 0.070 0.403 + 0.011 0.409 + 0.020 Cortical thickness (mm) 0.199 + 0.002 0.182 + 0.002 a 0.223 + 0.003 e 0.203 + 0.004 j,b 0.194 + 0.003 0.186 + 0.003 Polar MOI (mm4) 0.387 + 0.008 0.371 + 0.006 0.449 + 0.007 e 0.415 + 0.17 m 0.409 + 0.009 0.368 + 0.009 c Max MOI (mm4) 0.258 + 0.005 0.246 + 0.005 0.294 + 0.005 f 0.273 + 0.011 m 0.273 + 0.006 0.243 + 0.006 c Min MOI (mm4) 0.129 + 0.003 0.125 + 0.002 0.155 + 0.003 e 0.142 + 0.007 m 0.136 + 0.004 0.125 + 0.003 d Imax/Cmax (mm4) 0.268 + 0.005 0.253 + 0.004 d 0.307 + 0.004 e 0.285 + 0.010 m 0.281 + 0.006 0.258 + 0.005 d Imin/Cmin (mm4) 0.200 + 0.004 0.195 + 0.002 0.230 + 0.003 e 0.213 + 0.008 m 0.208 + 0.004 0.193 + 0.004 d Apparent density (mg/ccm HA) 1234.1 + 2.9 1218.3 + 3.7 c 1236.7 + 2.5 1216.5 + 4.4 c 1223.6 + 3.3 h 1216.3 + 3.2 Tissue density (mg/ccm HA) 1273.5 + 3.4 1259.8 + 3.9 d 1273.2 + 2.6 1253.6 + 3.9 b 1262.9 + 3.3 h 1256.3 + 3.1 ______a p < 10-4, b p < 10-3, c p < 0.01, d p < 0.05 vs. corresponding ground cohort e p < 10-4, f p < 10-3, g p < 0.01, h p < 0.05 vs. ground uninjected i p < 10-4, j p < 10-3, k p < 0.01, m p < 0.05 vs. flight uninjected

Table S2. ______

HUMERUS (TRABECULAR) ground flight ground flight ground flight uninjected uninjected + ACVR2B/Fc + ACVR2B/Fc Mstn -/- Mstn -/- ______

Bone volume percent (BV/TV) 8.83 + 0.75 4.56 + 0.50 b 15.06 + 0.79 e 16.03 + 1.44 i 8.73 + 0.59 7.50 + 0.66 k Trabecular thickness (µm) 52.0 + 1.2 47.5 + 1.6 d 49.9 + 0.9 47.4 + 0.8 d 48.5 + 0.9 h 48.4 + 1.5 Trabecular number (1/mm) 3.56 + 0.10 3.06 + 0.18 d 4.46 + 0.08 e 4.78 + 0.14 i 3.59 + 0.11 3.58 + 0.14 m Trabecular spacing (µm) 278.8 + 8.7 334.8 + 22.8 d 218.8 + 4.3 e 207.2 + 6.9 j 280.6 + 9.6 281.7 + 12.9 Connectivity density (1/mm3) 58.8 + 4.7 20.8 + 3.7 a 127.3 + 10.0 e 172.4 + 18.8 i,d 57.2 + 6.0 44.2 + 7.1 k Apparent density (mg/ccm HA) 162.2 + 7.3 124.4 + 3.8 b 215.1 + 5.9 e 216.0 + 11.4 i 156.2 + 4.8 147.1 + 5.5 k Tissue density (mm3) 897.8 + 7.6 893.2 + 8.5 884.3 + 6.1 867.2 + 7.8 m 873.1 + 6.4 h 886.6 + 9.1 Total volume (mm3) 0.82 + 0.01 0.80 + 0.03 0.89 + 0.03 h 0.92 + 0.03 m 0.87 + 0.02 h 0.86 + 0.03 Bone volume (mm3) 0.072 + 0.006 0.037 + 0.005 b 0.136 + 0.011 f 0.149 + 0.017 j 0.076 + 0.005 0.065 + 0.007 k Structure model index 2.58 + 0.12 3.15 + 0.07 b 1.68 + 0.10 e 1.54 + 0.17 i 2.40 + 0.07 2.66 + 0.10 d,j Bone surface (mm2) 3.77 + 0.23 2.18 + 0.27 b 6.74 + 0.45 e 7.69 + 0.73 i 4.07 + 0.26 3.62 + 0.34 k Specific bone surface (mm2) 54.78 + 1.93 62.89 + 1.72 c 50.97 + 0.93 53.34 + 1.57 j 55.47 + 1.01 58.48 + 1.87 Bone surface density (1/mm) 4.60 + 0.27 2.68 + 0.28 b 7.49 + 0.30 e 8.27 + 0.54 i 4.66 + 0.28 4.17 + 0.31 k BS/MV (1/mm) 5.06 + 0.33 2.82 + 0.31 b 8.84 + 0.43 e 9.93 + 0.81 i 5.12 + 0.33 4.52 + 0.37 k Degree of anisotropy 1.76 + 0.04 1.64 + 0.05 d 1.78 + 0.03 1.79 + 0.05 m 1.78 + 0.03 1.67 + 0.03 d ______a p < 10-4, b p < 10-3, c p < 0.01, d p < 0.05 vs. corresponding ground cohort e p < 10-4, f p < 10-3, g p < 0.01, h p < 0.05 vs. ground uninjected i p < 10-4, j p < 10-3, k p < 0.01, m p < 0.05 vs. flight uninjected

Table S3. ______

L2 VERTEBRAE ground flight ground flight ground flight uninjected uninjected + ACVR2B/Fc + ACVR2B/Fc Mstn -/- Mstn -/- ______

Bone volume fraction (BV/TV) 30.55 + 0.72 22.07 + 0.71 a 37.22 + 0.75 e 34.76 + 1.04 i 26.76 + 0.49 f 24.30 + 0.80 m,d Trabecular thickness (µm) 53.4 + 1.0 46.2 + 0.5 a 58.7 + 0.9 g 56.5 + 1.0 i 44.5 + 0.6 e 45.7 + 1.3 Trabecular number (1/mm) 5.37 + 0.06 5.03 + 0.09 c 5.98 + 0.05 e 5.90 + 0.15 j 5.57 + 0.09 5.27 + 0.08 d Trabecular spacing (µm) 172.0 + 2.3 187.8 + 4.1 c 156.3 + 1.0 e 159.4 + 3.9 j 171.4 + 2.9 182.7 + 3.7 d Connectivity density (1/mm3) 207.4 + 9.6 229.1 + 8.3 232.2 + 9.4 249.6 + 11.4 342.0 + 24.3 f 275.1 + 12.2 k,d Apparent density (mg/ccm HA) 367.8 + 7.4 286.5 + 6.9 a 425.0 + 7.1 e 406.9 + 11.0 i 321.1 + 4.9 f 302.5 + 8.0 Tissue density (mm3) 941.7 + 4.6 931.6 + 3.1 943.2 + 3.7 947.8 + 6.7 m 889.4 + 3.6 e 914.4 + 5.3 m,c Total volume (mm3) 1.82 + 0.05 1.88 + 0.03 1.93 + 0.05 1.84 + 0.04 2.04 + 0.05 g 1.95 + 0.04 Bone volume (mm3) 0.556 + 0.023 0.413 + 0.013 b 0.718 + 0.029 f 0.641 + 0.030 i 0.547 + 0.017 0.474 + 0.022 m,d Structure model index -0.07 + 0.06 0.71 + 0.06 a -0.75 + 0.10 e -0.36 + 0.09 m,d 0.11 + 0.04 h 0.36 + 0.07 k,c Bone surface (mm2) 22.49 + 0.70 20.71 + 0.42 d 25.80 + 0.92 g 24.40 + 0.85 k 26.95 + 0.87 f 23.49 + 0.67 k,c Specific bone surface (mm2) 40.53 + 0.80 50.46 + 0.82 a 35.85 + 0.64 f 38.15 + 0.85 m,d 49.16 + 0.84 e 49.83 + 1.38 Bone surface density (1/mm) 12.37 + 0.12 11.05 + 0.23 b 13.37 + 0.15 f 13.24 + 0.21 i 13.18 + 0.19 g 12.05 + 0.17 k,b BS/MV (1/mm) 17.83 + 0.32 14.21 + 0.41 a 21.32 + 0.43 e 20.35 + 0.61 i 18.00 + 0.33 15.93 + 0.35 k,b Degree of anisotropy 1.92 + 0.04 1.94 + 0.04 1.77 + 0.02 g 1.80 + 0.02 m 1.83 + 0.03 1.85 + 0.02 ______a p < 10-4, b p < 10-3, c p < 0.01, d p < 0.05 vs. corresponding ground cohort e p < 10-4, f p < 10-3, g p < 0.01, h p < 0.05 vs. ground uninjected i p < 10-4, j p < 10-3, k p < 0.01, m p < 0.05 vs. flight uninjected Table S4. ______

L3 VERTEBRAE ground flight ground flight ground flight uninjected uninjected + ACVR2B/Fc + ACVR2B/Fc Mstn -/- Mstn -/- ______

Bone volume fraction (BV/TV) 30.61 + 0.64 22.69 + 0.73 a 37.18 + 0.83 e 34.53 + 0.79 I,d 25.54 + 0.40 e 22.78 + 0.81 c Trabecular thickness (µm) 54.5 + 1.1 47.4 + 0.5 a 60.0 + 0.9 g 57.6 + 0.9 i 45.0 + 0.8 e 45.3 + 1.2 Trabecular number (1/mm) 5.40 + 0.07 4.93 + 0.10 b 5.87 + 0.09 f 5.78 + 0.13 i 5.37 + 0.08 5.03 + 0.10 d Trabecular spacing (µm) 172.2 + 2.2 194.1 + 4.9 c 157.9 + 2.3 f 162.6 + 3.5 i 179.7 + 3.4 193.1 + 4.7 d Connectivity density (1/mm3) 203.1 + 9.9 240.7 + 11.1 d 229.1 + 11.5 233.2 + 16.8 341.9 + 19.9 e 275.0 + 15.9 d Apparent density (mg/ccm HA) 366.9 + 6.5 290.6 + 6.9 a 427.1 + 7.4 e 406.0 + 7.9 i 310.9 + 3.9 e 287.1 + 8.1 d Tissue density (mm3) 941.5 + 4.6 933.5 + 2.4 950.8 + 4.5 952.3 + 4.8 k 889.3 + 4.1 e 908.7 + 3.8 I,c Total volume (mm3) 1.87 + 0.05 1.96 + 0.03 1.98 + 0.06 1.93 + 0.04 2.14 + 0.04 f 2.01 + 0.05 d Bone volume (mm3) 0.575 + 0.024 0.446 + 0.017 b 0.738 + 0.036 g 0.666 + 0.027 i 0.547 + 0.010 0.459 + 0.022 c Structure model index -0.05 + 0.06 0.63 + 0.07 a -0.72 + 0.12 f -0.40 + 0.06 I,d 0.15 + 0.03 h 0.50 + 0.07 c Bone surface (mm2) 23.00 + 0.75 21.81 + 0.59 26.23 + 1.13 h 25.03 + 0.95 m 27.12 + 0.46 f 23.16 + 0.96 c Specific bone surface (mm2) 40.08 + 0.72 49.26 + 0.70 a 35.46 + 0.69 f 37.53 + 0.72 i 49.49 + 0.76 e 50.79 + 1.28 Bone surface density (1/mm) 12.27 + 0.16 11.11 + 0.25 c 13.21 + 0.19 g 12.97 + 0.21 i 12.66 + 0.15 11.51 + 0.30 c BS/MV (1/mm) 17.69 + 0.34 14.40 + 0.45 a 21.07 + 0.52 e 19.84 + 0.49 i 17.01 + 0.25 14.93 + 0.50 c Degree of anisotropy 1.90 + 0.03 1.90 + 0.02 1.83 + 0.02 1.84 + 0.04 1.77 + 0.03 g 1.77 + 0.02 i ______a p < 10-4, b p < 10-3, c p < 0.01, d p < 0.05 vs. corresponding ground cohort e p < 10-4, f p < 10-3, g p < 0.01, h p < 0.05 vs. ground uninjected i p < 10-4, j p < 10-3, k p < 0.01, m p < 0.05 vs. flight uninjected Table S5. ______

L5 VERTEBRAE ground flight ground flight ground flight uninjected uninjected + ACVR2B/Fc + ACVR2B/Fc Mstn -/- Mstn -/- ______

Bone volume fraction (BV/TV) 29.62 + 0.78 21.32 + 0.63 a 36.20 + 0.94 e 34.01 + 0.84 i 25.70 + 0.69 g 22.53 + 0.88 c Trabecular thickness (µm) 56.5 + 1.0 49.6 + 0.9 a 61.1 + 1.1 g 59.4 + 1.1 i 47.6 + 0.9 e 47.5 + 1.4 Trabecular number (1/mm) 4.80 + 0.08 4.38 + 0.09 c 5.19 + 0.07 g 5.12 + 0.12 j 4.96 + 0.09 4.54 + 0.13 d Trabecular spacing (µm) 200.9 + 3.6 222.8 + 5.4 c 187.0 + 2.3 g 190.1 + 6.1 j 199.0 + 4.4 219.4 + 7.8 d Connectivity density (1/mm3) 200.6 + 10.0 218.4 + 8.3 235.4 + 10.4 h 237.6 + 16.3 315.8 + 20.3 f 254.7 + 13.9 m,d Apparent density (mg/ccm HA) 328.5 + 8.6 242.3 + 8.1 a 394.9 + 9.9 e 372.4 + 8.7 i 282.4 + 7.9 f 250.7 + 9.5 d Tissue density (mm3) 955.6 + 5.6 937.4 + 3.8 d 970.5 + 4.2 h 962.0 + 3.5 j 916.4 + 5.0 e 926.2 + 5.2 Total volume (mm3) 2.39 + 0.06 2.46 + 0.04 2.40 + 0.05 2.43 + 0.03 2.59 + 0.07 h 2.44 + 0.05 Bone volume (mm3) 0.711 + 0.034 0.523 + 0.016 b 0.869 + 0.029 g 0.825 + 0.016 i 0.664 + 0.01 0.551 + 0.026 c Structure model index -0.10 + 0.07 0.71+ 0.05 a -0.85 + 0.11 e -0.49 + 0.08 I,d 0.10 + 0.07 h 0.43 + 0.07 k,c Bone surface (mm2) 28.02 + 1.03 25.28 + 0.49 d 30.81 + 0.69 h 30.62 + 0.57 i 31.70 + 0.78 g 26.91 + 0.88 b Specific bone surface (mm2) 39.45 + 0.83 48.58 + 0.87 a 35.37 + 0.85 g 37.04 + 0.97 i 47.61 + 0.91 e 49.09 + 1.49 Bone surface density (1/mm) 11.69 + 0.16 10.30 + 0.20 a 12.83 + 0.11 e 12.61 + 0.15 i 12.26 + 0.22 h 11.00 + 0.26 c BS/MV (1/mm) 16.63 + 0.37 13.11 + 0.34 a 20.15 + 0.41 e 19.13 + 0.35 i 16.52 + 0.42 14.23 + 0.46 c Degree of anisotropy 1.82 + 0.01 1.83 + 0.02 1.75 + 0.03 h 1.74 + 0.02 k 1.73 + 0.03 g 1.73 + 0.02 k ______a p < 10-4, b p < 10-3, c p < 0.01, d p < 0.05 vs. corresponding ground cohort e p < 10-4, f p < 10-3, g p < 0.01, h p < 0.05 vs. ground uninjected i p < 10-4, j p < 10-3, k p < 0.01, m p < 0.05 vs. flight uninjected

Table S6. ______

ground flight recovery recovery Mstn -/- Mstn -/- uninjected + ACVR2B/Fc ______

FEMUR (TRABECULAR)

Bone volume fraction (BV/TV) 11.13 + 0.54 d 8.16 + 0.48 f 5.39 + 0.38 k 9.38 + 0.48 n Trabecular thickness (µm) 51.8 + 1.4 c 50.3 + 2.8 44.3 + 1.1 i 51.8 + 1.2 o Trabecular number (1/mm) 3.68 + 0.06 3.47 + 0.07 h 3.08 + 0.09 k 3.54 + 0.12 p Trabecular spacing (µm) 267.3 + 4.6 285.4 + 6.7 h 325.5 + 10.4 k 279.8 + 8.5 p Connectivity density (1/mm3) 95.3 + 6.5 71.4 + 5.7 h 60.9 + 6.5 106.8 + 13.9 q Apparent density (mg/ccm HA) 139.6 + 5.0 d 105.1 + 4.5 e 75.4 + 4.1 j 118.1 + 5.3 n Tissue density (mm3) 902.2 + 6.2 c 889.2 + 9.3 867.7 + 3.5 k 884.8 + 7.0 Total volume (mm3) 2.32 + 0.03 a 2.35 + 0.03 k 2.12 + 0.04 2.01 + 0.03 q Bone volume (mm3) 0.259 + 0.015 0.191 + 0.012 g 0.115 + 0.009 k 0.189 + 0.012 o Structure model index 2.18 + 0.10 2.65 + 0.09 g 2.88 + 0.08 2.45 + 0.05 o Bone surface (mm2) 13.25 + 0.55 10.75 + 0.56 g 7.20 + 0.52 m 10.26 + 0.74 p Specific bone surface (mm2) 52.62 + 1.45 d 58.61 + 2.77 66.54 + 1.94 j 55.87 + 0.93 o Bone surface density (1/mm) 5.70 + 0.19 4.58 + 0.21 f 3.39 + 0.21 m 5.10 + 0.30 o BS/MV (1/mm) 6.42 + 0.25 4.99 + 0.25 f 3.58 + 0.23 m 5.63 + 0.36 o Degree of anisotropy 1.45 + 0.04 1.34 + 0.02 h 1.38 + 0.02 m 1.41 + 0.02 ______

L4 VERTEBRAE

Bone volume fraction (BV/TV) 23.86 + 0.29 a 21.69 + 0.89 h 19.25 + 0.61 25.15 + 0.61 n Trabecular thickness (µm) 44.7 + 0.8 a 45.0 + 1.5 44.6 + 0.9 51.0 + 1.1 o Trabecular number (1/mm) 5.00 + 0.08 4.81 + 0.09 4.44 + 0.07 4.92 + 0.15 q Trabecular spacing (µm) 195.6 + 3.3 203.8 + 4.1 221.5 + 3.5 m 196.5 + 5.6 p Connectivity density (1/mm3) 340.4 + 23.7 b 275.4 + 12.0 h,k 237.0 + 17.2 263.2 + 23.4 Apparent density (mg/ccm HA) 267.0 + 2.8 a 249.7 + 9.6 225.2 + 6.7 285.8 + 5.6 n Tissue density (mm3) 897.8 + 4.2 a 907.4 + 2.3 i 914.2 + 5.0 925.0 + 3.2 Total volume (mm3) 2.47 + 0.07 d 2.39 + 0.08 2.29 + 0.03 2.21 + 0.06 Bone volume (mm3) 0.587 + 0.014 d 0.519 + 0.034 0.441 + 0.016 0.556 + 0.018 o Structure model index 0.30 + 0.03 a 0.58 + 0.07 g 0.83 + 0.04 0.46 + 0.05 o Bone surface (mm2) 29.90 + 0.90 d 26.74 + 1.21 h 23.12 + 0.66 25.15 + 0.80 Specific bone surface (mm2) 50.81 + 0.87 a 52.03 + 1.72 52.93 + 1.30 45.39 + 0.84 o Bone surface density (1/mm) 12.14 + 0.22 11.19 + 0.21 g 10.09 + 0.20 11.39 + 0.34 p BS/MV (1/mm) 15.95 + 0.32 14.31 + 0.40 g 12.51 + 0.32 15.24 + 0.57 p Degree of anisotropy 1.78 + 0.02 c 1.80 + 0.02 k 1.84 + 0.03 m 1.76 + 0.02 q ______a p < 10-4, b p < 10-3, c p < 0.01, d p < 0.05 vs. ground uninjected e p < 10-4, f p < 10-3, g p < 0.01, h p < 0.05 vs. ground Mstn -/- i p < 10-4, j p < 10-3, k p < 0.01, m p < 0.05 vs. flight uninjected n p < 10-4, o p < 10-3, p p < 0.01, q p < 0.05 vs. recovery uninjected Table S7. Top 50 most down-regulated proteins and RNAs as a result of ACVR2B/Fc treatment in ground control mice. Ratios of levels in ACVR2B/Fc-treated compared to uninjected mice are shown.

PLASMA BONE MUSCLE protein ratio p value gene ratio p value gene ratio p value

SERPINC1 0.35 1.70E-06 Pdzk1 0.02 1.41E-10 Gm21541 0.17 6.25E-05 DKK4 0.39 1.98E-02 Btnl6 0.06 4.27E-07 Mss51 0.24 9.97E-08 DKK2 0.44 2.29E-02 Akr1b7 0.08 6.67E-06 Pla2g2d 0.25 8.38E-04 AGER (sRAGE) 0.44 5.64E-03 Btnl4 0.17 2.90E-05 Slc6a2 0.27 7.51E-04 THBS2 0.45 2.61E-02 Itgad 0.21 1.37E-07 Ccl21a 0.34 2.29E-09 IGFBP2 0.47 2.96E-06 Pla2g2d 0.24 4.57E-12 Erdr1 0.36 9.66E-04 NXPH1 0.50 3.49E-02 Slco1a5 0.24 7.10E-05 Gkn3 0.36 3.26E-03 GALNT16 0.53 3.74E-04 Erdr1 0.27 4.18E-02 Aldh3a1 0.36 1.57E-03 KLK7 0.54 2.40E-02 Dock3 0.32 5.89E-05 Myl4 0.39 3.64E-10 DKK1 0.56 3.23E-02 Gdf15 0.35 1.03E-02 Pla2g5 0.40 1.31E-05 RBP4 0.57 4.08E-05 Ccr3 0.36 1.02E-04 Cd247 0.40 4.73E-03 IL2 0.59 1.65E-04 Mss51 0.37 2.14E-02 Igfn1 0.40 5.33E-03 TIMP4 0.61 2.11E-02 Kcnj10 0.37 1.16E-05 Inmt 0.42 8.67E-05 SNAI2 0.61 1.57E-03 Fcna 0.37 1.02E-04 Vwa3b 0.46 1.11E-02 PLD3 0.63 1.03E-03 Gpr50 0.38 3.36E-02 Chac1 0.46 2.15E-02 NPPA 0.63 3.67E-04 Cr2 0.41 8.10E-05 Tnnt2 0.47 1.23E-04 SHH 0.65 2.77E-02 Fcer2a 0.42 9.23E-04 H60c 0.47 1.86E-02 INHBA INHBB 0.65 8.37E-07 Ubd 0.43 1.95E-02 Fxyd6 0.48 6.62E-13 CLSTN1 0.67 3.13E-04 Tspan10 0.44 4.60E-02 Trhde 0.49 5.06E-03 COLEC11 0.69 3.01E-03 Prima1 0.44 4.62E-02 Tgtp1 0.50 1.97E-02 TGFB1 0.69 3.05E-02 Nxpe5 0.46 4.50E-03 Pitpnm3 0.50 1.44E-07 MSTN 0.69 4.86E-03 Spic 0.47 3.25E-03 Nnat 0.50 1.48E-02 SPOCK2 0.69 2.26E-02 Cd4 0.47 5.51E-04 Nebl 0.51 1.22E-03 BMP4 0.70 8.07E-05 Faim3 0.48 1.03E-02 Egfl8 0.51 1.35E-02 B3GALT2 0.71 5.89E-03 Ccr6 0.49 3.69E-02 S1pr4 0.52 1.69E-02 CA8 0.72 3.81E-02 Tgm1 0.50 1.84E-02 Has3 0.52 3.08E-03 BMP7 0.73 3.12E-06 Apol11a 0.50 4.07E-02 Prima1 0.54 6.07E-04 NPTXR 0.74 1.00E-03 E130309D14Rik 0.50 1.03E-02 3110021N24Rik 0.54 4.98E-02 LAMC2 0.75 1.78E-05 Gpr174 0.51 1.94E-02 Cyp2f2 0.55 3.27E-02 SFRP1 0.76 4.35E-03 Cxcr5 0.53 1.34E-02 6330403A02Rik 0.55 6.74E-04 CPM 0.76 2.30E-02 Nags 0.54 4.94E-02 Gm4070 0.55 3.85E-03 UNC5D 0.77 2.17E-04 Hmox1 0.54 1.84E-02 PYURF 0.56 2.50E-02 OMG 0.77 5.74E-04 Pnma1 0.54 3.51E-03 Kirrel3 0.56 1.02E-02 EPHB6 0.77 2.49E-02 Gfra2 0.56 5.51E-04 Igfbp3 0.57 2.15E-06 AMH 0.78 4.68E-04 Icam4 0.56 2.05E-02 Pcdhb20 0.58 4.85E-04 IHH 0.78 4.86E-05 Gfap 0.57 3.67E-02 Ptprz1 0.58 4.41E-02 SLIT2 0.78 1.94E-02 Gpr34 0.57 1.32E-02 Gucy2g 0.58 3.21E-03 HOMER2 0.78 2.46E-02 Sowaha 0.58 4.20E-02 Sema3g 0.58 4.60E-09 SPON2 0.79 1.33E-02 Lpar5 0.58 4.60E-02 Rab27a 0.58 1.05E-03 NHEJ1 0.79 3.27E-02 Rims3 0.59 2.13E-02 Id4 0.59 2.83E-02 BMP6 0.79 2.78E-03 H2-DMb2 0.59 2.51E-02 Avil 0.60 9.31E-04 GDF11 MSTN 0.79 4.49E-02 Cgn 0.59 4.92E-02 Chl1 0.60 4.42E-02 Human-virus 0.79 2.75E-02 H2-Ob 0.60 3.13E-02 Cd274 0.60 4.45E-02 RARRES2 0.79 3.03E-02 Ccr7 0.60 4.73E-02 Dgkb 0.60 1.96E-03 ETS2 0.79 1.86E-02 Samd3 0.61 4.07E-02 Zfp239 0.61 6.88E-03 GFRA1 0.79 7.84E-05 B3gnt7 0.62 3.23E-02 Gvin1 0.61 1.12E-02 RTN4R 0.79 5.59E-04 Gpr18 0.63 4.62E-02 Myl10 0.61 1.82E-02 HSPA1A 0.79 4.46E-03 Mylk3 0.63 4.50E-02 Hdac9 0.61 3.80E-02 COX7A2L 0.79 2.08E-03 Abcg3 0.63 4.24E-02 Sfrp5 0.61 4.56E-03 NSDHL 0.80 3.05E-02 Ly9 0.64 3.16E-02 Mb 0.61 2.41E-06

Table S8. Top 50 most up-regulated proteins and RNAs as a result of ACVR2B/Fc treatment in ground control mice. Ratios of levels in ACVR2B/Fc-treated compared to uninjected mice are shown.

PLASMA BONE MUSCLE protein ratio p value gene ratio p value gene ratio p value

TNFSF10/TRAIL 5.74 2.30E-02 Clec4f 29.70 4.49E-10 Vsig4 14.04 4.05E-09 GLTP 5.61 1.73E-02 Cd207 23.97 7.63E-13 Clec4d 8.72 1.54E-04 ST8SIA3 4.24 1.13E-02 Madcam1 17.07 5.38E-06 1700001O22Rik 6.98 8.03E-09 TNFSF11/RANKL 2.73 6.78E-07 Vsig4 12.11 5.67E-18 Prnd 6.55 8.97E-05 PLSCR3 2.55 1.64E-02 1700001O22Rik 12.06 3.32E-05 Dmp1 5.27 1.90E-04 ADCK4 2.44 3.66E-03 Nptx1 5.55 6.67E-06 Slc25a48 5.13 4.49E-03 MYL5 2.37 3.09E-02 Cxcl13 4.15 2.90E-05 Actc1 4.48 5.86E-10 VWF 2.32 4.27E-04 Sdr9c7 3.94 4.35E-02 Aspm 4.41 2.81E-03 G6B 2.17 2.14E-06 Mrgprb1 3.86 1.41E-03 Galr2 4.36 8.03E-09 PGRMC2 1.96 2.13E-06 Ankef1 3.84 4.62E-02 Opn1mw 4.01 5.54E-03 DUT 1.83 2.01E-05 Disp2 3.32 1.51E-05 Il1rapl2 3.90 3.60E-03 HP 1.81 4.30E-03 Adgb 3.31 2.43E-07 Cdk1 3.80 5.33E-03 FGL1 1.79 5.61E-03 Apoc1 3.26 3.19E-04 Slc15a5 3.63 1.67E-04 IGDCC4 1.77 1.18E-02 Gm4841 3.13 7.67E-03 Mki67 3.57 9.90E-03 TNNI2 1.77 2.19E-02 Panx3 3.05 3.25E-02 1810041L15Rik 3.47 5.00E-05 UROD 1.75 4.14E-07 Prnd 2.94 3.42E-02 Ckap2l 3.47 6.66E-03 RPN1 1.74 4.24E-03 Calml3 2.89 4.65E-02 Cenpf 3.41 2.42E-02 CTSD 1.70 1.89E-04 Sectm1a 2.88 1.85E-04 Apln 3.40 5.46E-05 INHBB 1.67 1.07E-02 Car12 2.88 4.33E-03 Vash2 3.35 1.66E-07 PMP2 1.65 4.15E-02 Crabp1 2.78 2.96E-03 Gm4841 3.32 1.26E-05 IGFBP5 1.64 2.24E-04 Acer2 2.76 6.68E-12 Cd300lb 3.28 8.62E-04 KPNB1 1.63 1.56E-05 Adh6b 2.73 2.90E-05 Trim59 3.19 8.57E-03 ITPA 1.58 3.00E-04 Gm21807 2.68 4.27E-02 Cacna1i 3.17 1.89E-05 OLFM2 1.58 1.84E-04 Susd4 2.68 1.47E-05 Spta1 3.13 1.79E-03 STC1 1.57 1.04E-03 Slc6a18 2.67 4.58E-02 Gm12185 3.06 3.68E-03 STIP1 1.54 8.82E-03 Pck1 2.65 1.43E-02 Gm5111 3.06 3.07E-05 HGFAC 1.53 2.16E-04 C2cd4c 2.64 6.71E-05 Ccr5 2.99 7.86E-03 NPS 1.53 7.07E-04 Lgals12 2.61 2.77E-03 Cep55 2.95 4.57E-02 STMN2 1.53 2.10E-02 Klb 2.60 4.01E-02 Cxcl13 2.92 6.60E-03 RPIA 1.53 6.55E-03 Notum 2.56 9.54E-03 Tlr5 2.86 2.62E-07 NUCB1 1.52 1.88E-03 Katnal2 2.56 3.36E-02 Kif5c 2.86 3.30E-05 GABARAPL2 1.50 1.39E-03 Lep 2.54 3.50E-02 Katnal2 2.74 9.64E-06 DNM2 1.50 2.31E-03 Cfd 2.53 2.51E-02 Slc17a7 2.66 2.04E-02 BAGE3 1.48 1.35E-04 Acvr1c 2.53 1.44E-02 A930003A15Rik 2.60 6.68E-04 ASPN 1.48 1.33E-04 Fras1 2.52 3.65E-04 Cyp4f39 2.58 6.11E-06 MATN3 1.48 3.43E-02 Oit3 2.52 7.73E-06 Fam65b 2.58 8.03E-09 DAPK1 1.47 7.59E-05 Arxes1 2.52 4.50E-02 Glp2r 2.56 3.10E-03 XPNPEP1 1.47 2.78E-03 Kcnj3 2.51 1.58E-03 Top2a 2.53 4.49E-02 NSFL1C 1.46 9.10E-04 Fetub 2.46 2.31E-02 Vwa3a 2.53 1.76E-04 PFDN5 1.46 1.03E-05 Cidec 2.45 5.39E-03 Scube2 2.51 3.74E-11 RRM1 1.46 4.22E-04 Klhdc7a 2.44 2.37E-02 Bai2 2.48 1.59E-03 NPIPB3 1.45 1.07E-05 Slc7a10 2.43 2.38E-02 Ucn2 2.47 1.65E-02 F9 1.45 2.35E-04 Gm12185 2.42 1.16E-04 Adam12 2.47 2.75E-03 IGBP1 1.45 7.10E-04 Lrrn2 2.41 1.11E-03 Chrna9 2.47 3.90E-02 TPT1 1.43 1.06E-02 Ccl24 2.41 1.19E-02 Pira2 2.46 2.62E-03 COL1A1 1.43 1.92E-02 Ramp3 2.39 1.24E-04 Wfdc17 2.45 3.26E-03 IGFALS 1.43 4.35E-04 C77370 2.35 3.87E-02 Tnfsf10 2.44 1.43E-07 BUB1 1.43 1.22E-02 Mest 2.35 1.82E-04 Cyp1a1 2.44 5.65E-05 SNCA 1.43 1.07E-02 Lrrc55 2.35 4.60E-02 Igf2 2.44 3.22E-08 CIRBP 1.43 4.72E-02 Gpr81 2.34 6.25E-03 Dpf1 2.37 1.56E-04

Table S9. Top 50 most down-regulated proteins and RNAs as a result of flight. Ratios of levels in uninjected flight compared to uninjected ground control mice are shown.

PLASMA BONE MUSCLE protein ratio p value gene ratio p value gene ratio p value

SFRP4 0.54 7.60E-03 Hist2h3c1 0.14 6.38E-03 Wnt16 0.15 1.08E-13 COL3A1 0.55 1.99E-03 Ptprt 0.21 1.49E-05 Gkn3 0.21 7.51E-06 IGFBP2 0.60 1.59E-04 Gabra4 0.26 1.25E-05 Dbp 0.22 3.11E-08 THBS4 0.66 1.70E-03 Dbp 0.28 1.84E-05 Nnat 0.24 1.33E-06 MFAP4 0.70 1.37E-02 Akr1b7 0.34 8.08E-04 Aldh3a1 0.26 8.67E-06 DPT 0.71 8.30E-03 Apol11a 0.35 1.12E-05 Cyfip2 0.28 5.34E-13 CTHRC1 0.71 6.11E-04 2010109I03Rik 0.35 2.66E-03 Ccnb1 0.28 4.59E-02 SCG3 0.72 4.05E-03 Ucp3 0.36 4.74E-04 Ucp3 0.29 7.08E-09 CD8A 0.72 4.92E-04 Cyp1a1 0.36 1.36E-03 Dkk2 0.30 3.91E-18 COLEC11 0.72 2.13E-02 Kera 0.37 2.53E-03 Unc13c 0.30 2.25E-05 RTN4R 0.73 8.53E-05 Kcnt1 0.38 7.21E-06 Chac1 0.31 4.59E-05 NPPA 0.73 3.67E-03 Slc10a4 0.38 1.99E-03 Gm826 0.31 2.96E-06 AMBP 0.74 1.21E-03 Apol10a 0.38 9.16E-06 Foxo6 0.32 9.71E-09 THBS3 0.74 1.24E-02 Pkd1l1 0.39 1.56E-06 Tfcp2l1 0.33 8.49E-09 SERPINC1 0.76 6.69E-03 Lrrc15 0.39 1.72E-03 Pcp4l1 0.33 1.44E-19 CASC4 0.76 1.50E-02 Phyhip 0.39 6.96E-07 Pm20d1 0.33 5.86E-08 FAIM3 0.79 1.07E-02 Slc30a10 0.40 9.38E-07 Cenpe 0.34 1.97E-02 GPC4 0.80 1.15E-02 Rbm44 0.40 1.14E-04 Fam69b 0.34 1.54E-06 ATP5O 0.81 1.12E-02 Chac1 0.40 9.42E-05 Lamb3 0.34 9.18E-05 MASP1 0.81 2.18E-02 Ccdc135 0.40 1.02E-04 Uts2b 0.34 4.17E-06 TFF2 0.82 6.83E-03 Tac2 0.41 2.57E-04 Slc9a4 0.35 3.82E-08 RNASE13 0.82 1.23E-02 Chst10 0.42 2.03E-08 Ostn 0.35 3.33E-13 C10orf35 0.83 8.98E-03 Abcg4 0.42 4.93E-06 Sgol2 0.36 6.30E-07 LMAN2L 0.84 3.55E-02 Cgn 0.43 1.02E-05 Cntfr 0.36 1.08E-13 CDH5 0.84 3.65E-03 Gm867 0.44 9.07E-07 Lep 0.37 1.51E-03 KRTAP2-4 0.84 7.76E-03 Vsnl1 0.44 1.07E-05 Aldh1b1 0.37 4.08E-05 IL2 0.85 3.95E-02 Cdc6 0.44 3.57E-06 Klhl33 0.37 7.89E-12 PCOLCE 0.85 2.00E-04 Zfpm1 0.44 7.75E-05 Plin5 0.38 5.11E-07 AOC1 0.86 4.11E-02 Ccne1 0.44 7.23E-07 Per2 0.38 5.54E-04 NELL2 0.86 2.09E-02 Mst1 0.45 3.24E-04 A930018M24Rik 0.39 9.46E-12 RGMA 0.87 1.08E-02 Per3 0.45 1.18E-09 Pdk4 0.39 3.08E-04 MIA 0.87 5.06E-03 Add2 0.45 1.09E-04 Hpdl 0.39 1.13E-07 GFRA2 0.88 3.31E-02 Apol8 0.45 2.34E-05 Map2k6 0.39 2.65E-15 EFEMP1 0.88 5.59E-03 Sec14l2 0.45 3.66E-07 Dgat2 0.39 3.47E-12 FBLN5 0.88 2.77E-02 Gfap 0.45 1.74E-05 Mybph 0.40 7.83E-08 TFRC 0.89 1.13E-02 Dock3 0.45 7.28E-05 Kif20b 0.40 7.68E-03 TMPRSS11A 0.89 3.00E-02 Btnl10 0.45 8.60E-05 Gm21955 0.40 4.24E-09 HTR6 0.90 4.80E-02 Rrm2 0.46 3.78E-06 Crip3 0.40 1.55E-02 APOF 0.90 2.59E-02 6030468B19Rik 0.46 8.50E-05 Fgfbp1 0.40 1.05E-11 PEBP1 0.90 4.01E-02 Cpox 0.46 2.24E-06 Ptgfr 0.41 5.51E-10 CASC4 0.90 1.24E-02 Dnah12 0.46 1.14E-04 Cdh4 0.41 8.15E-05 CCDC80 0.91 4.16E-02 Prss35 0.46 1.19E-04 Ccbe1 0.41 1.90E-07 TRDMT1 0.92 2.37E-02 Sh3tc2 0.47 4.26E-06 Zfp750 0.42 8.83E-03 CRP 0.92 2.55E-02 Per2 0.47 4.17E-09 Cxcl9 0.42 7.55E-03 ADPRH 0.92 4.07E-02 Plek2 0.47 8.29E-06 Coro2a 0.42 1.57E-05 VCAM1 0.92 3.44E-02 Cyp2b10 0.47 5.63E-03 Nme5 0.42 1.42E-05 ANGPTL1 0.92 1.59E-02 Magee2 0.47 5.61E-03 Tmem14a 0.43 8.95E-07 PRCP 0.92 4.21E-03 Prokr2 0.47 7.19E-03 Adora1 0.43 3.42E-04 CDKN3 0.93 1.04E-03 Slc6a20a 0.47 1.48E-05 Papln 0.43 1.15E-04 GAS7 0.94 4.23E-02 Kntc1 0.47 1.15E-05 Tfrc 0.44 1.31E-09

Table S10. Top 50 most up-regulated proteins and RNAs as a result of flight. Ratios of levels in uninjected flight compared to uninjected ground control mice are shown.

PLASMA BONE MUSCLE protein ratio p value gene ratio p value gene ratio p value

AGER (sRAGE) 3.61 1.87E-02 Csrp3 15.95 6.66E-06 Tnfrsf12a 9.19 2.14E-16 MYBPC1 3.23 4.09E-04 Pnmt 14.86 1.54E-11 Npas2 9.01 1.34E-07 MYOM2 2.96 1.71E-02 Chrna9 14.50 3.75E-06 Adamts4 7.91 6.31E-09 TNNI2 2.81 1.84E-03 Cytl1 10.95 1.27E-02 Ankrd1 7.61 3.54E-25 POMC 2.39 9.13E-04 Gm20481 10.87 9.09E-03 Rrad 6.61 7.73E-11 LAP3 2.29 8.75E-04 Ankrd2 10.47 2.17E-04 Spon2 6.48 1.53E-09 HSPA1A 2.00 1.04E-02 Tnfrsf12a 8.31 3.15E-10 Lcn2 6.29 3.01E-09 POMC 1.94 1.64E-03 Agrp 8.21 3.40E-04 Socs3 5.97 3.49E-09 CLIC5 1.89 2.53E-02 5031434C07Rik 6.56 4.06E-03 Ces5a 5.85 5.44E-09 HAPLN4 1.88 8.01E-04 Xirp1 6.40 6.61E-04 Adamts8 5.79 5.44E-17 KAL1 1.79 1.17E-04 Ces5a 6.27 4.32E-04 Chrna9 5.74 1.29E-07 LEAP2 1.77 1.43E-03 Mustn1 5.88 1.48E-08 Csrp3 5.68 1.18E-16 XPNPEP1 1.74 3.19E-02 Atf3 5.80 9.57E-08 Atf3 5.64 5.22E-12 HSPA1A 1.71 7.68E-03 Ankrd1 5.78 3.21E-05 Baiap2l2 5.57 1.64E-10 CACNB4 1.68 1.63E-02 Npas2 5.66 2.40E-05 Ccl7 5.37 5.09E-03 HSPA1A 1.66 4.38E-03 Gm1078 5.57 3.29E-03 Fat2 5.36 1.26E-03 ALDOA 1.61 2.19E-02 Prg4 5.49 1.67E-02 Xirp1 5.34 6.21E-20 HSPA1B 1.59 3.09E-02 Myog 5.32 5.86E-05 Pnmt 5.14 1.69E-17 HMGCS1 1.58 2.67E-03 Ppp1r27 5.25 1.45E-04 Opn1mw 5.10 1.00E-04 MFAP5 1.58 4.34E-03 Eda2r 4.84 2.27E-06 Mustn1 4.89 1.42E-21 CHGB 1.54 6.50E-03 Fzd10 4.70 4.72E-03 Timp1 4.84 3.03E-08 DCLK1 1.53 5.87E-05 Gnmt 4.68 1.75E-07 Gm20481 4.77 8.64E-05 CAPZA1 1.53 2.55E-03 Klb 4.68 6.30E-05 Chi3l1 4.68 5.47E-06 SUMF2 1.50 7.20E-04 1700001O22Rik 4.60 1.33E-02 Clca6 4.61 7.14E-04 DNASE1L2 1.49 1.00E-02 Lmcd1 4.58 1.33E-04 Elf3 4.60 3.10E-07 ADH7 1.48 2.72E-03 Myh13 4.57 4.36E-02 Scn3b 4.39 5.06E-20 SPON2 1.47 6.28E-04 Alb 4.54 2.66E-03 Arntl 4.34 2.87E-10 BMP1 1.46 4.29E-04 Has1 4.54 4.28E-03 A930003A15Rik 4.28 1.31E-09 C14orf93 1.45 2.89E-02 Rrad 4.51 1.30E-05 Ankrd2 4.15 3.00E-15 S100A4 1.45 6.79E-04 Hspa1a 4.44 5.50E-04 Igf2bp2 4.03 1.39E-10 SPOCK2 1.44 5.18E-04 Scn3b 4.44 7.80E-07 Panx1 4.01 3.45E-24 AIMP1 1.43 6.97E-04 Hspb7 4.43 1.03E-02 Zap70 3.97 2.01E-07 SLIT2 1.42 2.14E-02 Tnni1 4.41 4.25E-02 Rims4 3.95 8.84E-17 ALDOC 1.39 6.00E-06 Hspb1 4.33 1.46E-04 St8sia2 3.92 5.32E-09 AKR1B1 1.39 1.77E-02 Myl6b 4.22 1.82E-03 Eda2r 3.78 1.25E-12 HSPA1A 1.39 3.91E-03 Hspa1b 4.20 9.84E-04 Hspa1b 3.73 5.78E-09 IL18 1.37 2.33E-02 Bex1 4.18 8.30E-06 Ucn2 3.66 2.00E-05 HSPA1A 1.37 5.95E-04 Sln 4.14 2.73E-02 Serpina3n 3.65 1.95E-06 PCDH8 1.36 4.58E-02 Flnc 4.01 1.49E-02 Spsb4 3.63 1.57E-14 HSPA1A 1.36 7.08E-03 Mettl21c 4.00 1.20E-04 Nr4a3 3.59 1.36E-07 NME1 1.35 8.38E-03 Pkp1 3.99 1.70E-02 Hspa1a 3.57 6.45E-10 APOH 1.35 7.63E-04 Pdlim3 3.96 1.18E-03 E2f8 3.51 1.50E-04 LGALS3 1.34 3.74E-03 March4 3.96 2.91E-03 Auts2 3.50 7.64E-14 PSAT1 1.34 4.44E-03 Ankef1 3.93 1.66E-02 Myh10 3.46 2.23E-23 IGFALS 1.34 2.40E-04 Tecrl 3.89 1.42E-03 Mapk4 3.35 1.20E-06 FH 1.34 1.41E-03 Srrm4 3.82 4.58E-03 Vash2 3.33 1.18E-08 WNK3 1.34 8.90E-03 Pcp4 3.77 2.29E-02 Wisp1 3.31 3.38E-07 CD27 1.33 1.74E-03 Myh6 3.73 3.52E-02 Ros1 3.28 1.56E-07 CDC42BPA 1.33 1.40E-02 Ttc9 3.71 1.93E-05 Atp1b4 3.28 3.92E-13 GOT1 1.33 1.79E-05 Fhl1 3.71 7.32E-03 Gnmt 3.20 8.41E-13